Cancer Research
- Xenomics Announces License With Asuragen For NPM1 Leukemia Diagnostics
-
DRobbins@Xenomics.com Asuragen Contact: Lori Brisbin Director of Marketing Asuragen, Inc. +1-512-681-5200 ...
Article - Anna Ohlden - Oct 29 2007 - 7:31am
- Helsinn Healthcare And MGI PHARMA Announce Submission Of Supplemental New Drug Application For Aloxi(R) Oral Capsules
-
IR@mgipharma.com Contact: Helsinn Healtcare SA, Paolo Ferrari, Head of Marketing- Oncology and Supportive Care, ...
Article - Anna Ohlden - Oct 30 2007 - 6:54am
- 4SC And AiCuris Begin Collaboration For The Discovery Of Anti-Infective Drug Candidates
-
info@aicuris.com For more information please contact: Bettina von Klitzing, Manager Investor Relations und Public ...
Article - Anna Ohlden - Feb 5 2008 - 3:31am
- Helsinn Healthcare SA Announces The Launch Of Aloxi(R) (Palonosetron) In The UK
-
Reynolds; Contact person: HELSINN HEALTHCARE SA: Paolo Ferrari- Head of Marketing, Oncology & Supportive ...
Article - Anna Ohlden - Feb 11 2008 - 5:31am
- Human Stem Cells Grow In Self-Assembled Mini-Lab
-
the hyaluronic acid solution. The two interacted on contact, creating a solid. By varying the mold, ...
Article - News Staff - Mar 27 2008 - 1:40pm
- First Patient Enrolled In Global Phase III Study Of Bevacizumab And Trastuzumab In Early Breast Cancer
-
North American Contact, Holly McCalmon of NSABP, +1-412-330-4616, holly.mccalmon@nsabp.org ...
Article - Anna Ohlden - May 27 2008 - 12:32pm
- Effective Management Of Breakthrough Pain In Patients With Cancer Using Nycomed's Intranasal Fentanyl Spray
-
available on request. Please contact Ulf Jonson (contact above). References (1). Kaasa S. A randomised, ...
Article - Anna Ohlden - May 29 2008 - 8:33am
- Rosetta Genomics And Rabin Medical Center Announce A Collaboration Focused On MicroRNA-Based Diagnostics
-
media@rosettagenomics.com Investors Ron Kamienchick T: +1-(646)-509-1893 E: investors@rosettagenomics.com Contact: Media, ...
Article - Anna Ohlden - Jun 25 2008 - 8:32am
- Rosetta Genomics And Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary And Metastatic Tumors In
-
Contact: Media& Investors, Ron Kamienchick, T: +1-646-509-1893, E: investors@rosettagenomics.com ...
Article - Anna Ohlden - Jul 9 2008 - 8:33am
- Organizational Changes At Silence Therapeutics
-
Securities Limited, +44-(0)20-7776-1200; or U.S. Contacts: Lisa Rivero, +1-978-745-4200, ext. 106, or Tim ...
Article - Anna Ohlden - Jul 17 2008 - 11:31am
Know Science And Want To Write?
Donate or Buy SWAG
Please donate so science experts can write
for the public.
At Science 2.0, scientists are the journalists,
with no political bias or editorial control. We
can't do it alone so please make a difference.
We are a nonprofit science journalism
group operating under Section 501(c)(3)
of the Internal Revenue Code that's
educated over 300 million people.
You can help with a tax-deductible
donation today and 100 percent of your
gift will go toward our programs,
no salaries or offices.
